公司資料

Ibio Inc 股價、新聞與催化劑

股票代碼:
IBIO
交易所:
AMEX
產業:
Biopharma
所在地:
United States

股票表現

1.45 USD (+1.40%)

收盤價

最後更新: 2026年8月17日

87.4M USD

市值

股價為何變動

As of Aug 17, 2026, IBIO closed up 1.40% at $1.45. No new same-company headline was identified in the current news window.

公司概覽

AI-Enabled Antibody Discovery

iBio develops antibodies using computational discovery and engineering platforms designed to improve target selection and molecular properties.

IBIO-600

IBIO-600 is a long-acting anti-myostatin antibody intended to preserve lean mass and improve body composition during obesity treatment.

Cardiopulmonary Expansion

The pipeline also includes a bispecific antibody program for pulmonary hypertension associated with heart failure with preserved ejection fraction.

未來催化劑

  • iBio has received Australian regulatory clearance to initiate a first-in-human Phase 1 study of IBIO-600.

近期新聞

  1. 01
  2. 02
  3. 03
  4. 04
  5. 05

相似股票

商業成熟度、治療領域或催化劑模式相近的同業公司。